NCT02396433

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

Phase I/II Clinical Trial of the Combination of Carboplatin, Eribulin Mesylate, and E7449 in Patients With BRCA-Related Cancers

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: The University of Texas Health Science Center at San Antonio · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Non-randomized, open-label, multi-center, phase I/II, dose-escalation study of the combination of carboplatin, eribulin, and E7449.

Detailed description

This is a phase I/II clinical trial of the combination of carboplatin, eribulin, and E7449. A cycle will be defined as 21 days. Carboplatin will be given on day 1 of each cycle. Eribulin will be given on days 1 and 8 of each cycle. E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.

Conditions

• Cancer of the Breast

Interventions

Type	Name	Description
DRUG	Carboplatin	Carboplatin will be given on day 1 of each cycle.
DRUG	Eribulin	Eribulin will be given on days 1 and 8 of each cycle.
DRUG	E7449	E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.

Timeline

• Start date: 2015-04-01
• Primary completion: 2015-04-01
• Completion: 2015-04-01
• First posted: 2015-03-24
• Last updated: 2015-08-25